Answer
Its selected licence is as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome, meaning it is added to an existing treatment plan.
Sources for this answer
- Rufinamide Brown & Burk 200 mg Film-coated Tablets — Current selected SmPCemc · Summary of Product Characteristics
- Rufinamide Eisai Oral Suspension — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.